

Osprey Technology Featured at Key Meeting of Cardiovascular Professionals

Key Highlights

- AVERT™ trial results will be the first scientific presentation of the annual Society for Cardiovascular Angiography and Interventions (SCAI) meeting, May 4th in the US
- Presentation of findings from the 578 patient trial evaluating dye savings and reduction in Contrast-Induced Acute Kidney Injury (CI-AKI) in patients treated with AVERT
- Selection as the first scientific presentation reflects physician interest in methods to protect poor kidney function patients from the harmful effects of x-ray dye
- The SCAI meeting is one of the world's largest gatherings of heart specialty physicians and professionals

Melbourne, Australia and Minnesota, United States – April 26, 2016 – Osprey Medical Inc. (ASX: OSP) is pleased to announce its AVERT System clinical trial results will be featured at the SCAI annual meeting in Orlando, Florida, on May 4-7, 2016.

A Late-Breaking Clinical Trial presentation of results from the 578 patient AVERT randomized controlled trial will lead the meeting when it opens on May 4 and will be presented by the meeting Program Chair and trial Principal Investigator, Professor Roxana Mehran.

Trial results have already lead to the AVERT System and its second generation DyeVert™ System receiving US Food and Drug Administration (FDA) clearance for dye savings, image quality and reflux reduction claims. The late breaking trial presentation will report study findings and sub-group analysis of the impact of the AVERT System on dye savings and reduction of CI-AKI.


The DyeVert System will also be featured at a Satellite Program during the SCAI conference discussing contrast reduction methods in the effort to address CI-AKI.

Osprey CEO Mike McCormick said “we are pleased that our trial was selected as the first scientific presentation of the annual SCAI meeting; this reflects the physician community’s interest in reducing contrast dose to avoid CI-AKI”.

The SCAI meeting is one of the world’s largest gatherings of cardiovascular physicians, nurses and hospital administrators delivering the latest developments and innovations in the field.



Late-Breaking Clinical Trial Presentations

<p>May 4 1:15 PM</p>	<p>Effect of the AVERT Contrast Modulation System on Contrast Dose Reduction and Acute Kidney Injury After Coronary Angiography and PCI — Roxana Mehran, MD, FSCAI</p>	
--------------------------	--	---

About Osprey

Osprey Medical is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. The Company's core technologies originated from research conducted by Dr. David Kaye at Melbourne's Baker IDI Heart and Diabetes Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage. The Company's DyeVert™ System is a next-generation product that reduces contrast while maintaining image quality in a self-adjusting easy-to-use design. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Contact details:

Media

Gavin Lower

Buchan Consulting

T: (613) 8866 1215

glower@buchanwe.com.au

Investors

Rebecca Wilson

Buchan Consulting

M: (61) 417 382 391

rwilson@buchanwe.co.au

Company

Doug Schoenberg

VP of Marketing

T: (952) 955 8230

dschoenberg@ospreymed.com